In relation to a $400 million senior secured term loan arrangement that partially funded the purchase of Astria Therapeutics, Inc., Gibson Dunn represented BioCryst Pharmaceuticals, Inc.

Galecto, Inc. was represented by Gibson Dunn in setting up an at-the-market facility for the selling of up to $150 million worth of shares of its common stock.

Atossa Therapeutics, Inc. was represented by Gibson Dunn in the establishment of an at-the-market facility for the sale of up to $50 million worth of its common stock.

As the main investor in the up to $400 million private placement funding for Immunic, Inc., a late-stage biotechnology firm leading the way in the creation of innovative oral treatments for neurological and gastrointestinal disorders, Gibson Dunn represented BVF Partners L.P.

As lead investor in the up to $40 million private placement funding for AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical business creating innovative small molecule treatments based on its boron chemistry platform, Gibson Dunn represented Coastlands Capital.

BMO Financial Group consented to sell Stonepeak its Transportation Finance and Vendor Finance divisions, together with associated loan portfolios in the US and Canada.

Dianthus Therapeutics, Inc. was represented by Gibson Dunn in a public offering of its common stock and pre-funded warrants to buy common stock. Dianthus received total gross proceeds from the offering of about $719 million.

Merck is receiving advice from a Gibson Dunn antitrust team about its $6.7 billion purchase of the clinical-stage oncology business Terns Pharmaceuticals, Inc. With TERN-701, a possible best-in-class option for the treatment of some patients with chronic myeloid leukemia, Merck’s expanding presence in hematology is strengthened by the purchase of Terns.

For Entera Bio Ltd., a clinical stage company focused on creating oral peptide and protein replacement therapies for major unmet medical needs where an oral tablet form holds the potential to transform the standard of care, Gibson Dunn represented BVF Partners L.P. in its up to $24.5 million private placement financing.

Today, Akin announced the entrance of a top-tier private equity team in New York and London, which includes Jonathan Hamill, Gerald Brant, Jeffrey Kochian, and Brittany Harrison, all of whom are returning to the company. In the whole range of control private equity, complex mergers and acquisitions (M&A), and capital solutions transactions, the group offers…